Tumor metastasis, recurrence, and therapeutic resistance are the main reasons for the failure of clinical cancer treatment. Studies have found that ...

In a paper published in National Science Review, an international team of scientists report a coordination nanomedicine ...

Vimentin is a type III intermediate filament (IF) protein typically expressed in cells that differentiate into connective ...

Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner. Targeting vimentin and/or the long ...

Changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth by increasing cancer stemness in an oestrogen independent manner.

New research has found that changes to the intermediate filament (IF) protein, vimentin, were found to promote tumor growth.

This important study focused on characterizing clonally derived MSC populations from the synovium of normal and osteoarthritis (OA) patients, demonstrating their potential to regenerate cartilage in ...

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid ...

Scientists have uncovered a mechanism for reinvigorating the immune system to stop it from flagging when it’s fighting ...

Many foods are often advertised for their antioxidant properties. Antioxidants counteract what are known as reactive oxygen ...

Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the way for improved immunotherapies.

PADCEV is an antibody-drug conjugate (ADC) that delivers cell-killing medicine directly to certain cancer cells. [7] However, it can also affect normal cells and cause side effects. PADCEV is a ...